PhaseBio Pharmaceuticals Capex/Depreciation

Capex/Depreciation of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex/Depreciation growth rates and interactive chart.


Highlights and Quick Summary

  • Capex/Depreciation for the quarter ending March 31, 2022 was -0.08 (a -97.02% decrease compared to previous quarter)
  • Year-over-year quarterly Capex/Depreciation decreased by -81.14%
  • Annual Capex/Depreciation for 2021 was -1.49 (a -46.25% decrease from previous year)
  • Annual Capex/Depreciation for 2020 was -2.78 (a -49.62% decrease from previous year)
  • Annual Capex/Depreciation for 2019 was -5.52 (a 386.83% increase from previous year)
  • Twelve month Capex/Depreciation ending March 31, 2022 was -1.35 (a -9.54% decrease compared to previous quarter)
  • Twelve month trailing Capex/Depreciation increased by 218.02% year-over-year
Trailing Capex/Depreciation for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-1.35 -1.49 -0.71 -0.43
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex/Depreciation of PhaseBio Pharmaceuticals

Most recent Capex/Depreciationof PHAS including historical data for past 10 years.

Interactive Chart of Capex/Depreciation of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Capex/Depreciation for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.08
2021 -2.73 -4.91 -0.43 -0.28 -1.49
2020 -0.16 -3.24 -9.14 -12.19 -2.78
2019 -2.72 -7.9 -8.02 -2.71 -5.52
2018 -3.83 -0.11 -0.81 -0.22 -1.13
2017 -0.43 -3.0 -2.25
2016 0.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology